SYRE earnings date and last-quarter result: last quarter miss, P/E -45.49. Updated 2026-07-23.
Spyre Therapeutics (SYRE) Research Hub
Spyre Therapeutics (SYRE) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 92.91 USD (+2.86%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -45.49, market cap 6.03B. This hub links to the full technical, earnings and options research available for SYRE.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 92.91 USD (+2.86%) |
| 52-week range | 77.05 USD – 110.18 USD |
| Trend regime | Range |
| 14-day RSI | 68.3 (Bullish) |
| Trailing P/E | -45.49 |
| Market cap | 6.03B |
| Dividend yield | 0.00% |
Available research for SYRE
Covered Call on SYRE: how it works, illustrative setup around the real 92.91 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on SYRE: how it works, illustrative setup around the real 92.91 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on SYRE: how it works, illustrative setup around the real 92.91 USD price, max profit/loss, breakeven and when to use it. Educational.
SYRE technical analysis: range, last 92.91 USD, RSI 68.3, 52w range 77.05 USD–110.18 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is SYRE in?
Spyre Therapeutics (SYRE) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is SYRE in an uptrend or downtrend?
As of 2026-10-26, SYRE is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is SYRE's trailing P/E ratio?
SYRE's trailing P/E is -45.49, with a market cap of 6.03B. See the earnings research page for full valuation detail.